Which has preferable earnings and valuation, ACRV or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A

Is ACRV or DMAC more profitable?

Acrivon Therapeutics' return on equity of -70.14% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% DiaMedica Therapeutics N/A -77.76% -69.43%

Is ACRV or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% Q32 Bio N/A 50.17% 29.49%

Acrivon Therapeutics (ACRV) Competitors

$2.00 -0.04 (-1.96%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.00 +0.00 (+0.25%)

As of 09/11/2026 07:30 PM Eastern

Compare

ACRV vs. IRD, DMAC, QTTB, AGEN, and XFOR

Should you buy Acrivon Therapeutics stock or one of its competitors? Acrivon Therapeutics's main competitors and comparable companies include Opus Genetics (IRD), DiaMedica Therapeutics (DMAC), Q32 Bio (QTTB), Agenus (AGEN), and X4 Pharmaceuticals (XFOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acrivon Therapeutics compare to Opus Genetics?

Acrivon Therapeutics (NASDAQ:ACRV) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Acrivon Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Acrivon Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Acrivon Therapeutics' return on equity of -70.14% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Opus Genetics has higher revenue and earnings than Acrivon Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Opus Genetics	$14.20M	35.16	-$49.59M	-$1.35	N/A

Acrivon Therapeutics currently has a consensus target price of $13.50, suggesting a potential upside of 575.00%. Opus Genetics has a consensus target price of $11.92, suggesting a potential upside of 97.40%. Given Acrivon Therapeutics' higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Opus Genetics had 37 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 38 mentions for Opus Genetics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Opus Genetics' score of 0.55 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Opus Genetics	Positive

Summary

Acrivon Therapeutics and Opus Genetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Acrivon Therapeutics compare to DiaMedica Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 1.87 equaled DiaMedica Therapeutics'average media sentiment score.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
DiaMedica Therapeutics	Very Positive

Acrivon Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 575.00%. DiaMedica Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 85.47%. Given Acrivon Therapeutics' higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Acrivon Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Acrivon Therapeutics' return on equity of -70.14% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

Summary

Acrivon Therapeutics beats DiaMedica Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Q32 Bio?

Acrivon Therapeutics (NASDAQ:ACRV) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Q32 Bio's return on equity of 50.17% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Q32 Bio	N/A	50.17%	29.49%

Q32 Bio has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Q32 Bio	$53.74M	6.15	$29.82M	$3.00	3.70

In the previous week, Q32 Bio had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 6 mentions for Q32 Bio and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Q32 Bio's score of 1.19 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Q32 Bio	Positive

Acrivon Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 575.00%. Q32 Bio has a consensus price target of $31.00, suggesting a potential upside of 179.28%. Given Acrivon Therapeutics' higher probable upside, equities research analysts plainly believe Acrivon Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Acrivon Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Summary

Q32 Bio beats Acrivon Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Agenus?

Agenus (NASDAQ:AGEN) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Agenus has a net margin of 69.33% compared to Acrivon Therapeutics' net margin of 0.00%. Agenus' return on equity of -47.68% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Agenus currently has a consensus target price of $19.50, indicating a potential upside of 180.98%. Acrivon Therapeutics has a consensus target price of $13.50, indicating a potential upside of 575.00%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Agenus had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 2 mentions for Agenus and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Agenus' score of 0.28 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Agenus	Neutral
Acrivon Therapeutics	Very Positive

Agenus has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	2.74	$120K	$2.58	2.69
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Agenus has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

61.5% of Agenus shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Agenus beats Acrivon Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Acrivon Therapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -63.05% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Acrivon Therapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	9.88	-$79.20M	-$1.20	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, X4 Pharmaceuticals had 11 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 12 mentions for X4 Pharmaceuticals and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat X4 Pharmaceuticals' score of 0.35 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
X4 Pharmaceuticals	Neutral
Acrivon Therapeutics	Very Positive

X4 Pharmaceuticals presently has a consensus price target of $11.25, indicating a potential upside of 221.43%. Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 575.00%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

X4 Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Summary

X4 Pharmaceuticals and Acrivon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$85.71M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-1.06	14.18	274.94	25.33
Price / Sales	N/A	1,375.01	685.45	111.12
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	0.56	15.12	10.33	6.20
Net Income	-$77.90M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-6.10%	-4.34%	-3.32%	-2.35%
1 Month Performance	16.28%	-0.02%	-0.41%	-2.77%
1 Year Performance	31.58%	40.64%	19.21%	7.63%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	4.024 of 5 stars	$2.00 -2.0%	$13.50 +575.0%	+29.0%	$85.71M	N/A	N/A	58
IRD Opus Genetics	3.2327 of 5 stars	$4.36 -6.7%	$10.69 +145.5%	+328.4%	$359.93M	$9.86M	N/A	14	Trending News Analyst Forecast Insider Trade Options Volume
DMAC DiaMedica Therapeutics	1.873 of 5 stars	$6.54 -3.1%	$12.00 +83.5%	-11.1%	$354.32M	N/A	N/A	20	Positive News
QTTB Q32 Bio	3.9738 of 5 stars	$11.66 -2.8%	$31.00 +165.9%	+490.4%	$346.58M	$53.74M	3.88	39	Positive News
AGEN Agenus	2.7885 of 5 stars	$7.45 -9.6%	$19.50 +161.8%	+46.4%	$338.55M	$114.20M	2.91	440

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. IRD, DMAC, QTTB, AGEN, and XFOR

How does Acrivon Therapeutics compare to Opus Genetics?

Summary

How does Acrivon Therapeutics compare to DiaMedica Therapeutics?

Summary

How does Acrivon Therapeutics compare to Q32 Bio?

Summary

How does Acrivon Therapeutics compare to Agenus?

Summary

How does Acrivon Therapeutics compare to X4 Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. IRD, DMAC, QTTB, AGEN, and XFOR

How does Acrivon Therapeutics compare to Opus Genetics?

Which has more volatility & risk, ACRV or IRD?

Is ACRV or IRD more profitable?

Which has preferable valuation & earnings, ACRV or IRD?

Do analysts rate ACRV or IRD?

Do institutionals & insiders hold more shares of ACRV or IRD?

Does the media favor ACRV or IRD?

Summary

How does Acrivon Therapeutics compare to DiaMedica Therapeutics?

Does the media favor ACRV or DMAC?

Do analysts recommend ACRV or DMAC?

Which has more risk & volatility, ACRV or DMAC?

Do institutionals & insiders have more ownership in ACRV or DMAC?

Which has preferable earnings and valuation, ACRV or DMAC?

Is ACRV or DMAC more profitable?

Summary

How does Acrivon Therapeutics compare to Q32 Bio?

Do institutionals & insiders have more ownership in ACRV or QTTB?

Is ACRV or QTTB more profitable?

Which has preferable valuation and earnings, ACRV or QTTB?

Does the media favor ACRV or QTTB?

Do analysts prefer ACRV or QTTB?

Which has more volatility and risk, ACRV or QTTB?

Summary

How does Acrivon Therapeutics compare to Agenus?

Is AGEN or ACRV more profitable?

Do analysts rate AGEN or ACRV?

Does the media refer more to AGEN or ACRV?

Which has higher valuation & earnings, AGEN or ACRV?

Which has more volatility and risk, AGEN or ACRV?

Do insiders and institutionals believe in AGEN or ACRV?

Summary

How does Acrivon Therapeutics compare to X4 Pharmaceuticals?

Is XFOR or ACRV more profitable?

Which has preferable valuation and earnings, XFOR or ACRV?

Do institutionals & insiders believe in XFOR or ACRV?

Does the media refer more to XFOR or ACRV?

Do analysts rate XFOR or ACRV?

Which has more volatility & risk, XFOR or ACRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools